Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma

Akira Tari, Yasuhiko Kitadai, Ritsuo Mouri, Hidehiko Takigawa, Hideki Asaoku, Keiichiro Mihara, Katsuyoshi Takata, Megumu Fujihara, Tadashi Yoshino, Tadashi Koga, Shunji Fujimori, Shinji Tanaka, Kazuaki Chayama

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and Aim: Few reports have demonstrated the effectiveness of treatments for intestinal follicular lymphoma (FL) because of the limited number of patients who undergo comprehensive small intestinal examinations. This study compared the efficacy of rituximab-combined chemotherapy in patients with asymptomatic and low tumor burden (LTB) intestinal FL, according to the criteria of the Groupe d'Etude des Lymphomes Folliculaires, with that of a "watch and wait" (W&W) approach. Methods: The endoscopic examination for entire gastrointestinal tracts was performed in 29 Japanese patients with intestinal FL. These patients had CD21-positive follicular dendritic cells arranged in a duodenal pattern. In a prospective, two-center, open-label trial, this study evaluated the efficacy of rituximab-combined chemotherapy ([cyclophosphamide, doxorubicin, vincristine, and prednisone] or [cyclophosphamide, vincristine, and prednisone]) and prolonged treatment with rituximab (R-Chemo+prolongedR) in 14 patients and compared their outcomes with those of 15 patients managed with a W&W approach. Results: Four patients managed with the W&W plan showed worsening macroscopic findings, lesion area enlargement, or clinical stage progression but stayed on this plan because they had LTB and experienced no changes in bowel function. In the R-Chemo+prolongedR group, all patients achieved complete remission; recurrence occurred in one patient, who was subsequently managed with the W&W plan because of LTB. There were no significant differences in progression-free survival between the two groups (P = 0.1045). Overall survival was 100% in both groups. Conclusions: The prognoses of patients with asymptomatic intestinal FL and LTB who were managed with a W&W strategy were comparable with those of patients receiving R-Chemo+prolongedR.

Original languageEnglish
JournalJournal of Gastroenterology and Hepatology (Australia)
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Follicular Lymphoma
Drug Therapy
Tumor Burden
Vincristine
Prednisone
Cyclophosphamide
Rituximab
Follicular Dendritic Cells
Doxorubicin
Disease-Free Survival
Gastrointestinal Tract

Keywords

  • Intestinal follicular lymphoma
  • Low tumor burden
  • Rituximab-combined chemotherapy
  • Treatment
  • Watch and wait

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. / Tari, Akira; Kitadai, Yasuhiko; Mouri, Ritsuo; Takigawa, Hidehiko; Asaoku, Hideki; Mihara, Keiichiro; Takata, Katsuyoshi; Fujihara, Megumu; Yoshino, Tadashi; Koga, Tadashi; Fujimori, Shunji; Tanaka, Shinji; Chayama, Kazuaki.

In: Journal of Gastroenterology and Hepatology (Australia), 01.01.2018.

Research output: Contribution to journalArticle

Tari, A, Kitadai, Y, Mouri, R, Takigawa, H, Asaoku, H, Mihara, K, Takata, K, Fujihara, M, Yoshino, T, Koga, T, Fujimori, S, Tanaka, S & Chayama, K 2018, 'Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma', Journal of Gastroenterology and Hepatology (Australia). https://doi.org/10.1111/jgh.14100
Tari, Akira ; Kitadai, Yasuhiko ; Mouri, Ritsuo ; Takigawa, Hidehiko ; Asaoku, Hideki ; Mihara, Keiichiro ; Takata, Katsuyoshi ; Fujihara, Megumu ; Yoshino, Tadashi ; Koga, Tadashi ; Fujimori, Shunji ; Tanaka, Shinji ; Chayama, Kazuaki. / Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. In: Journal of Gastroenterology and Hepatology (Australia). 2018.
@article{e922b833980441ef8c5a33d14e302c30,
title = "Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma",
abstract = "Background and Aim: Few reports have demonstrated the effectiveness of treatments for intestinal follicular lymphoma (FL) because of the limited number of patients who undergo comprehensive small intestinal examinations. This study compared the efficacy of rituximab-combined chemotherapy in patients with asymptomatic and low tumor burden (LTB) intestinal FL, according to the criteria of the Groupe d'Etude des Lymphomes Folliculaires, with that of a {"}watch and wait{"} (W&W) approach. Methods: The endoscopic examination for entire gastrointestinal tracts was performed in 29 Japanese patients with intestinal FL. These patients had CD21-positive follicular dendritic cells arranged in a duodenal pattern. In a prospective, two-center, open-label trial, this study evaluated the efficacy of rituximab-combined chemotherapy ([cyclophosphamide, doxorubicin, vincristine, and prednisone] or [cyclophosphamide, vincristine, and prednisone]) and prolonged treatment with rituximab (R-Chemo+prolongedR) in 14 patients and compared their outcomes with those of 15 patients managed with a W&W approach. Results: Four patients managed with the W&W plan showed worsening macroscopic findings, lesion area enlargement, or clinical stage progression but stayed on this plan because they had LTB and experienced no changes in bowel function. In the R-Chemo+prolongedR group, all patients achieved complete remission; recurrence occurred in one patient, who was subsequently managed with the W&W plan because of LTB. There were no significant differences in progression-free survival between the two groups (P = 0.1045). Overall survival was 100{\%} in both groups. Conclusions: The prognoses of patients with asymptomatic intestinal FL and LTB who were managed with a W&W strategy were comparable with those of patients receiving R-Chemo+prolongedR.",
keywords = "Intestinal follicular lymphoma, Low tumor burden, Rituximab-combined chemotherapy, Treatment, Watch and wait",
author = "Akira Tari and Yasuhiko Kitadai and Ritsuo Mouri and Hidehiko Takigawa and Hideki Asaoku and Keiichiro Mihara and Katsuyoshi Takata and Megumu Fujihara and Tadashi Yoshino and Tadashi Koga and Shunji Fujimori and Shinji Tanaka and Kazuaki Chayama",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jgh.14100",
language = "English",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma

AU - Tari, Akira

AU - Kitadai, Yasuhiko

AU - Mouri, Ritsuo

AU - Takigawa, Hidehiko

AU - Asaoku, Hideki

AU - Mihara, Keiichiro

AU - Takata, Katsuyoshi

AU - Fujihara, Megumu

AU - Yoshino, Tadashi

AU - Koga, Tadashi

AU - Fujimori, Shunji

AU - Tanaka, Shinji

AU - Chayama, Kazuaki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Aim: Few reports have demonstrated the effectiveness of treatments for intestinal follicular lymphoma (FL) because of the limited number of patients who undergo comprehensive small intestinal examinations. This study compared the efficacy of rituximab-combined chemotherapy in patients with asymptomatic and low tumor burden (LTB) intestinal FL, according to the criteria of the Groupe d'Etude des Lymphomes Folliculaires, with that of a "watch and wait" (W&W) approach. Methods: The endoscopic examination for entire gastrointestinal tracts was performed in 29 Japanese patients with intestinal FL. These patients had CD21-positive follicular dendritic cells arranged in a duodenal pattern. In a prospective, two-center, open-label trial, this study evaluated the efficacy of rituximab-combined chemotherapy ([cyclophosphamide, doxorubicin, vincristine, and prednisone] or [cyclophosphamide, vincristine, and prednisone]) and prolonged treatment with rituximab (R-Chemo+prolongedR) in 14 patients and compared their outcomes with those of 15 patients managed with a W&W approach. Results: Four patients managed with the W&W plan showed worsening macroscopic findings, lesion area enlargement, or clinical stage progression but stayed on this plan because they had LTB and experienced no changes in bowel function. In the R-Chemo+prolongedR group, all patients achieved complete remission; recurrence occurred in one patient, who was subsequently managed with the W&W plan because of LTB. There were no significant differences in progression-free survival between the two groups (P = 0.1045). Overall survival was 100% in both groups. Conclusions: The prognoses of patients with asymptomatic intestinal FL and LTB who were managed with a W&W strategy were comparable with those of patients receiving R-Chemo+prolongedR.

AB - Background and Aim: Few reports have demonstrated the effectiveness of treatments for intestinal follicular lymphoma (FL) because of the limited number of patients who undergo comprehensive small intestinal examinations. This study compared the efficacy of rituximab-combined chemotherapy in patients with asymptomatic and low tumor burden (LTB) intestinal FL, according to the criteria of the Groupe d'Etude des Lymphomes Folliculaires, with that of a "watch and wait" (W&W) approach. Methods: The endoscopic examination for entire gastrointestinal tracts was performed in 29 Japanese patients with intestinal FL. These patients had CD21-positive follicular dendritic cells arranged in a duodenal pattern. In a prospective, two-center, open-label trial, this study evaluated the efficacy of rituximab-combined chemotherapy ([cyclophosphamide, doxorubicin, vincristine, and prednisone] or [cyclophosphamide, vincristine, and prednisone]) and prolonged treatment with rituximab (R-Chemo+prolongedR) in 14 patients and compared their outcomes with those of 15 patients managed with a W&W approach. Results: Four patients managed with the W&W plan showed worsening macroscopic findings, lesion area enlargement, or clinical stage progression but stayed on this plan because they had LTB and experienced no changes in bowel function. In the R-Chemo+prolongedR group, all patients achieved complete remission; recurrence occurred in one patient, who was subsequently managed with the W&W plan because of LTB. There were no significant differences in progression-free survival between the two groups (P = 0.1045). Overall survival was 100% in both groups. Conclusions: The prognoses of patients with asymptomatic intestinal FL and LTB who were managed with a W&W strategy were comparable with those of patients receiving R-Chemo+prolongedR.

KW - Intestinal follicular lymphoma

KW - Low tumor burden

KW - Rituximab-combined chemotherapy

KW - Treatment

KW - Watch and wait

UR - http://www.scopus.com/inward/record.url?scp=85044184335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044184335&partnerID=8YFLogxK

U2 - 10.1111/jgh.14100

DO - 10.1111/jgh.14100

M3 - Article

C2 - 29377265

AN - SCOPUS:85044184335

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

ER -